Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as increase in prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-4H8Z4LpNMLEuOnnx
The Global cancer gene therapy market is segmented on the basis of type, therapy, end-user and regional
Based on the type, global cancer gene therapy market is segmented as:
Gene Induced Immunotherapy
Tumour Antigen Gene Delivery
Cytokine Gene Delivery
Oncolytic Virotherapy
Adenoviruses
Adeno Associated Virus
Lentiviruses
Alpha Virus
Retrovirus
Herpes Simplex Virus
Vaccinia virus
Simian Virus
Gene Transfer/ Gene Replacement
Electroporation
Magnetofection
Naked / Plasmid Vectors
Gene Gun
Sonoporation
Based on the therapy, global cancer gene therapy market is segmented as:
Retroviral Therapy
Adenoviral Therapy
Based on the end-user, global cancer gene therapy market is segmented as:
Hospitals
Oncology institutes
Biotechnological companies
Clinical Research Labs
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-c654SbFYO64MsOhu
Global cancer gene therapy market is highly fragmented with small biotech firms holding a chunk of the overall industry share. Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy. As per WHO, cancer incidence is projected to rise by 50% to reach 15 Mn by the end of this decade. This alarming increase in number of patients and side effects associated with various chemotherapy drugs necessitates this as a potential treatment approach addressing the growing global burden of the cancers. Small biotech firms dominate the global cancer gene therapy market than the bigger players. The players are constantly engaged in R&D in order to develop novel methods to treat various life threatening diseases.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-14mlyhjMGhVjZqa3
Some of the major companies operating in the global cancer gene therapy market are Urigen Pharmaceuticals Inc. (U.S), GenVec.Inc (U.S), Oxford BioMedica (U.K), Vical (U.S), ANI Pharmaceuticals, Inc. (U.S), and Genzyme Corporation (U.S). Novartis AG (Switzerland), and Cell Medica (U.K.)
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"